Pain – Identifying and Commercializing First-in-Class Innovation

The active pain pipeline is populated by 796 products across all stages of development, which exhibit a highly diverse range of molecular targets. GBI Research’s analyses identified 122 first-in-class programs in active development, constituting 13.6% of the pipeline and acting on 65 first-in-class molecular targets, indicating a high degree of innovation. This is in stark contrast to the pain therapeutics market, which has been largely characterized by only incremental product innovation over the last decade, as most market segments continue to be dominated by long-established active pharmaceutical ingredients and the concomitant mechanisms of action. Moderate-to-severe pain continues to be dominated by opioids that are increasingly being reformulated to offer abuse-resistance, while mild pain is effectively treated with Non-Steroidal Anti-Inflammatory Drugs (NSAID). However, significant unmet needs remain, as chronic pain and some neuropathic pain subtypes do not respond well to existing therapies, which are not adequate to treat associated hypersensitization and do not align to the underlying molecular pathophysiological profile.

Pain is a complex and multifaceted disorder with a complex interplay between different pathological processes, and different pain subtypes exhibit distinct underlying etiologies and pathophysiologies. While technological advances and extensive research efforts have furthered the understanding of these complex underpinnings, gaps remain. However, these insights have translated into the expanding pool of novel therapeutic targets, as reflected by the highly innovative pipeline. GBI Research’s proprietary analysis shows that early-stage, first-in-class programs exhibit a higher level of diversity with respect to novel therapeutic targets. The significant diversity in terms of targets is a reflection of the complex underpinnings of distinct pain subtypes. Although the pipeline continues to feature established therapies, the range of mechanisms of action employed by novel compounds is extremely diverse, with the vast majority residing in the Preclinical stage.

With 107 first-in-class products available for strategic consolidations, a wide variety of investment opportunities are available for licensing deals or co-development deals in pain. This will be encouraged by the growing unmet need for chronic pain therapies, and an increased understanding of the distinct underlying pathophysiologies of distinct pain sub-types, allowed by technological advances. Among these, some first-in-class products have demonstrated promising Preclinical evidence and have significant potential to become game-changing products, representing high-reward investments.

Complete report on Identifying and Commercializing First-in-Class Innovation of “Pain” addiction with 1 market data tables and 48 figures, spread across 106 pages is http://www.rnrmarketresearch.com/frontier-pharma-pain-identifying-and-commercializing-first-in-class-innovation-market-report.html . (This is a premium report price at US$6995 for a single user PDF license)

Scope:

• A brief introduction to pain, including the different subtypes of pain, pathophysiology, and overview of pharmacotherapy and treatment algorithms
• The changing molecular target landscape between market and pipeline and particular focal points of innovation in the pipeline
• A comprehensive review of the pipeline for first-in-class therapies, analyzed on the basis of stage of development, molecule type and molecular target
• Identification and assessment of first-in-class molecular targets with a particular focus on early-stage programs of which clinical utility has yet to be evaluated, as well as literature reviews on novel molecular targets
• Assessment of the licensing and co-development deal landscape for pain therapies and benchmarking of deals involving first-in-class versus non-first-in-class-products

Inquire for discount on this report at http://www.rnrmarketresearch.com/contacts/discount?rname=320681 .

Reasons to buy:                                                                                                         

• Understand the focal shifts in molecular targets in the pain therapeutics pipeline
• Understand the distribution of pipeline programs by phase of development, molecule type and molecular target
• Access a scientific and clinical analysis of first-in-class developmental programs for pain, benchmarked against non-first-in-class targets.
• Access a list of the first-in-class therapies potentially open to deal-making opportunities

More reports on Pain Management :

Pain Partnering 2010-2015

The Pain Partnering 2010-2015 report provides understanding and access to the pain partnering deals and agreements entered into by the worlds leading healthcare companies.
Trends in pain partnering deals
Top pain deals by value
Deals listed by company A-Z, industry sector, stage of development, technology type
The Pain Partnering 2010-2015 provides understanding and access to the pain partnering deals and agreements entered into by the worlds leading healthcare companies.

Complete report is available at http://www.rnrmarketresearch.com/pain-partnering-2007-2013-market-report.html .